Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Mar;4(1):28-41.
doi: 10.2174/1874473711104010028.

Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review

Affiliations
Review

Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review

Michael A Yokell et al. Curr Drug Abuse Rev. 2011 Mar.

Abstract

The diversion, misuse, and non-medically supervised use of buprenorphine and buprenorphine/naloxone by opioid users are reviewed. Buprenorphine and buprenorphine/naloxone are used globally as opioid analgesics and in the treatment of opioid dependency. Diversion of buprenorphine and buprenorphine/naloxone represents a complex medical and social issue, and has been widely documented in various geographical regions throughout the world. We first discuss the clinical properties of buprenorphine and its abuse potential. Second, we discuss its diversion and illicit use on an international level, as well as motivations for those activities. Third, we examine the medical risks and benefits of buprenorphine's non-medically supervised use and misuse. These risks and benefits include the effect of buprenorphine's use on HIV risk and the risk of its concomitant use with other medications and drugs of abuse. Finally, we discuss the implications of diversion, misuse, and non-medically supervised use (including potential measures to address issues of diversion); and potential areas for further research.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

Similar articles

Cited by

References

    1. Degenhardt L, Hall W, Warner-Smith M. Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sex Transm Infect. 2006;82(Suppl 3):iii56–63. - PMC - PubMed
    1. Strassels SA. Economic burden of prescription opioid misuse and abuse. J Managed Care Pharm. 2009;15(7):1–7. - PMC - PubMed
    1. United Nations Office on Drugs and Crime. World Drug Report. 2007.
    1. World Health Organization. WHO Drug Information. 3. Vol. 19. 2005. p. 72.
    1. World Health Organization, Office on Drugs and Crime. Drug Report. 2007.

Publication types

MeSH terms